{
 "disease": "ewing-sarcoma",
 "label": "Ewing sarcoma",
 "url": "https://usebiotransfer.org/disease/ewing-sarcoma/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "a75bc77250e1",
  "targets": "6240db0549f1"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "EWSR1",
   "ensembl": "ENSG00000182944",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "FLI1",
   "ensembl": "ENSG00000151702",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CD99",
   "ensembl": "ENSG00000002586",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "IGF1R",
   "ensembl": "ENSG00000140443",
   "n_drug_entries": 20,
   "n_distinct_drugs": 20,
   "drugs": {
    "AEW-541": "PHASE_1",
    "AXL-1717": "PHASE_2",
    "BIIB-022": "PHASE_1",
    "BMS-754807": "PHASE_2",
    "CIXUTUMUMAB": "PHASE_2",
    "CONTELTINIB": "PHASE_1_2",
    "DALOTUZUMAB": "PHASE_2",
    "FIGITUMUMAB": "PHASE_3",
    "GANITUMAB": "PHASE_3",
    "ISTIRATUMAB": "PHASE_2",
    "KW-2450": "PHASE_1_2",
    "LINSITINIB": "PHASE_3",
    "MASOPROCOL": "APPROVAL",
    "MECASERMIN": "APPROVAL",
    "MECASERMIN RINFABATE": "UNKNOWN",
    "PL-225B": "PHASE_1",
    "ROBATUMUMAB": "PHASE_2",
    "TEPROTUMUMAB": "APPROVAL",
    "VELIGROTUG": "PHASE_3",
    "XL-228": "PHASE_1"
   },
   "approved": [
    "MASOPROCOL",
    "MECASERMIN",
    "TEPROTUMUMAB"
   ],
   "n_approved": 3,
   "approved_for": {
    "MASOPROCOL": [
     "prostate cancer"
    ],
    "MECASERMIN": [
     "Growth delay",
     "hypothyroidism",
     "Laron syndrome"
    ],
    "TEPROTUMUMAB": [
     "Graves ophthalmopathy",
     "Graves disease"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "PARP1",
   "ensembl": "ENSG00000143799",
   "n_drug_entries": 13,
   "n_distinct_drugs": 12,
   "drugs": {
    "2X-121": "PHASE_2",
    "AMELPARIB DIHYDROCHLORIDE DIHYDRATE": "PHASE_2",
    "E-7016": "PHASE_2",
    "NIRAPARIB": "APPROVAL",
    "NIRAPARIB TOSYLATE": "APPROVAL",
    "OLAPARIB": "APPROVAL",
    "PAMIPARIB": "APPROVAL",
    "RUCAPARIB": "APPROVAL",
    "RUCAPARIB CAMSYLATE": "APPROVAL",
    "SENAPARIB": "PHASE_3",
    "TALAZOPARIB": "APPROVAL",
    "VELIPARIB": "APPROVAL"
   },
   "approved": [
    "NIRAPARIB",
    "NIRAPARIB TOSYLATE",
    "OLAPARIB",
    "PAMIPARIB",
    "RUCAPARIB",
    "RUCAPARIB CAMSYLATE",
    "TALAZOPARIB",
    "VELIPARIB"
   ],
   "n_approved": 8,
   "approved_for": {
    "NIRAPARIB": [
     "fallopian tube neoplasm",
     "peritoneal neoplasm",
     "ovarian neoplasm",
     "ovarian cancer"
    ],
    "NIRAPARIB TOSYLATE": [
     "ovarian cancer",
     "fallopian tube cancer",
     "peritoneum cancer",
     "fallopian tube carcinoma",
     "ovarian carcinoma",
     "peritoneal neoplasm"
    ],
    "OLAPARIB": [
     "ovarian cancer",
     "ovarian carcinoma",
     "pancreatic neoplasm",
     "prostate carcinoma",
     "breast neoplasm",
     "ovarian neoplasm",
     "fallopian tube cancer",
     "primary peritoneal carcinoma"
    ],
    "PAMIPARIB": [],
    "RUCAPARIB": [
     "ovarian cancer"
    ],
    "RUCAPARIB CAMSYLATE": [
     "ovarian cancer",
     "ovarian neoplasm",
     "ovarian carcinoma"
    ],
    "TALAZOPARIB": [
     "breast cancer",
     "breast neoplasm",
     "prostate cancer",
     "breast carcinoma"
    ],
    "VELIPARIB": []
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "STAG2",
   "ensembl": "ENSG00000101972",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CDKN2A",
   "ensembl": "ENSG00000147889",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "KDM1A",
   "ensembl": "ENSG00000004487",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "BOMEDEMSTAT": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CDK4",
   "ensembl": "ENSG00000135446",
   "n_drug_entries": 17,
   "n_distinct_drugs": 15,
   "drugs": {
    "ABEMACICLIB": "APPROVAL",
    "AG-24322": "PHASE_1",
    "ALVOCIDIB": "PHASE_3",
    "AT-7519": "PHASE_2",
    "AZD-5438": "PHASE_1",
    "MILCICLIB": "PHASE_2",
    "PALBOCICLIB": "APPROVAL",
    "PHA-793887": "PHASE_1",
    "RG-547": "PHASE_1",
    "RGB-286638": "PHASE_1",
    "RIBOCICLIB": "APPROVAL",
    "RONICICLIB": "PHASE_2",
    "TRILACICLIB": "APPROVAL",
    "UCN-01": "PHASE_2",
    "VORUCICLIB": "PHASE_1"
   },
   "approved": [
    "ABEMACICLIB",
    "PALBOCICLIB",
    "RIBOCICLIB",
    "TRILACICLIB"
   ],
   "n_approved": 4,
   "approved_for": {
    "ABEMACICLIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "PALBOCICLIB": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ],
    "RIBOCICLIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "TRILACICLIB": [
     "small cell lung carcinoma",
     "myelosuppression"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "ERG",
   "ensembl": "ENSG00000157554",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "NKX2-2",
   "ensembl": "ENSG00000125820",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "CD99": {
    "n": 0,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CD99",
     "MIC2"
    ]
   },
   "IGF-1R": {
    "n": 12,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00474760",
      "title": "Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2013-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00560235",
      "title": "Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors",
      "status": "COMPLETED",
      "last_update": "2015-10-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00562380",
      "title": "AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-07-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00563680",
      "title": "QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors",
      "status": "COMPLETED",
      "last_update": "2016-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00609141",
      "title": "IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor",
      "status": "COMPLETED",
      "last_update": "2014-06-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00617890",
      "title": "A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)",
      "status": "TERMINATED",
      "last_update": "2018-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00668148",
      "title": "A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma",
      "status": "COMPLETED",
      "last_update": "2018-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00831844",
      "title": "Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2015-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01614795",
      "title": "Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma",
      "status": "COMPLETED",
      "last_update": "2018-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02306161",
      "title": "Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02546544",
      "title": "Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma",
      "status": "COMPLETED",
      "last_update": "2019-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04129151",
      "title": "Palbociclib + Ganitumab In Ewing Sarcoma",
      "status": "TERMINATED",
      "last_update": "2024-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "IGF-1R",
     "IGF1R",
     "ganitumab",
     "cixutumumab",
     "figitumumab"
    ]
   },
   "GD2": {
    "n": 9,
    "n_observational": 1,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00003022",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00445965",
      "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00743496",
      "title": "A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03356782",
      "title": "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03373097",
      "title": "Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03635632",
      "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04238819",
      "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma",
      "status": "COMPLETED",
      "last_update": "2026-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04433221",
      "title": "Combination Immunotherapy Targeting Sarcomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06839703",
      "title": "International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 3,
     "n_observational": 0,
     "n_active": 3,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT03356782",
       "title": "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03373097",
       "title": "Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-02-05",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03635632",
       "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "GD2",
     "dinutuximab"
    ]
   },
   "B7-H3": {
    "n": 5,
    "n_observational": 1,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04897321",
      "title": "B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",
      "status": "RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07172958",
      "title": "Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07222735",
      "title": "Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02982941",
      "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-02-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04433221",
      "title": "Combination Immunotherapy Targeting Sarcomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 3,
     "n_observational": 0,
     "n_active": 3,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04897321",
       "title": "B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",
       "status": "RECRUITING",
       "last_update": "2026-05-19",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07172958",
       "title": "Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)",
       "status": "RECRUITING",
       "last_update": "2026-08-13",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07222735",
       "title": "Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas",
       "status": "RECRUITING",
       "last_update": "2026-02-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "B7-H3",
     "CD276"
    ]
   },
   "STEAP1": {
    "n": 0,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "STEAP1"
    ]
   },
   "LSD1": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03514407",
      "title": "A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma",
      "status": "TERMINATED",
      "last_update": "2025-10-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03600649",
      "title": "Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas",
      "status": "UNKNOWN",
      "last_update": "2023-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05266196",
      "title": "A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)",
      "status": "UNKNOWN",
      "last_update": "2023-08-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "LSD1",
     "seclidemstat"
    ]
   },
   "PARP": {
    "n": 9,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04901702",
      "title": "Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma",
      "status": "RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06827717",
      "title": "Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma",
      "status": "RECRUITING",
      "last_update": "2025-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01286987",
      "title": "Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01583543",
      "title": "Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma",
      "status": "COMPLETED",
      "last_update": "2017-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01858168",
      "title": "Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma",
      "status": "COMPLETED",
      "last_update": "2025-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02044120",
      "title": "ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma",
      "status": "COMPLETED",
      "last_update": "2021-01-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02116777",
      "title": "Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-03-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03155620",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03233204",
      "title": "Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)",
      "status": "COMPLETED",
      "last_update": "2024-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PARP",
     "olaparib",
     "talazoparib",
     "niraparib"
    ]
   }
  },
  "by_drug": {
   "ABEMACICLIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02644460",
      "title": "Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04238819",
      "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma",
      "status": "COMPLETED",
      "last_update": "2026-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05440786",
      "title": "CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ALVOCIDIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00012181",
      "title": "Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas",
      "status": "COMPLETED",
      "last_update": "2013-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CIXUTUMUMAB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00609141",
      "title": "IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor",
      "status": "COMPLETED",
      "last_update": "2014-06-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00668148",
      "title": "A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma",
      "status": "COMPLETED",
      "last_update": "2018-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00831844",
      "title": "Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2015-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01614795",
      "title": "Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma",
      "status": "COMPLETED",
      "last_update": "2018-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FIGITUMUMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00474760",
      "title": "Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2013-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00560235",
      "title": "Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors",
      "status": "COMPLETED",
      "last_update": "2015-10-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GANITUMAB": {
    "n": 4,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00562380",
      "title": "AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-07-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00563680",
      "title": "QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors",
      "status": "COMPLETED",
      "last_update": "2016-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02306161",
      "title": "Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04129151",
      "title": "Palbociclib + Ganitumab In Ewing Sarcoma",
      "status": "TERMINATED",
      "last_update": "2024-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LINSITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02546544",
      "title": "Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma",
      "status": "COMPLETED",
      "last_update": "2019-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MECASERMIN RINFABATE": {
    "n": 1,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00563680",
      "title": "QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors",
      "status": "COMPLETED",
      "last_update": "2016-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NIRAPARIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02044120",
      "title": "ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma",
      "status": "COMPLETED",
      "last_update": "2021-01-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OLAPARIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01583543",
      "title": "Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma",
      "status": "COMPLETED",
      "last_update": "2017-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01858168",
      "title": "Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma",
      "status": "COMPLETED",
      "last_update": "2025-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03155620",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03233204",
      "title": "Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)",
      "status": "COMPLETED",
      "last_update": "2024-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PALBOCICLIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03155620",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03526250",
      "title": "Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)",
      "status": "COMPLETED",
      "last_update": "2026-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03709680",
      "title": "Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04129151",
      "title": "Palbociclib + Ganitumab In Ewing Sarcoma",
      "status": "TERMINATED",
      "last_update": "2024-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ROBATUMUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00617890",
      "title": "A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)",
      "status": "TERMINATED",
      "last_update": "2018-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TALAZOPARIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04901702",
      "title": "Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma",
      "status": "RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01286987",
      "title": "Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02116777",
      "title": "Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-03-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRILACICLIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06699472",
      "title": "A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib",
      "status": "RECRUITING",
      "last_update": "2024-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}